Digital technologies, including generative AI, are transforming how organizations engage patients from research and development through commercialization. GenAI is set to become a workforce partner for 90% of organizations globally in 2025. By integrating these tools thoughtfully, companies can accelerate drug discovery, optimize clinical trials, enhance patient care, and improve access to therapies.

• Identify current barriers to fully utilizing generative AI in patient engagement
• Explore how digital methods can enhance patient access, support, and affordability
• Examine the role of technology in accelerating drug development, clinical trials, and commercialization

Authentic representation is essential to truly advancing patient engagement in rare diseases. Too often, the lived experiences of patients and caregivers are misrepresented through generic or inaccurate imagery and narratives, creating a disconnect that can reinforce stigma and delay recognition and care. Drawing on Chiesi Global Rare Diseases' It's Rare for Me and True Faces of Rare initiatives, learn key lessons on how elevating real patient stories and visuals can reshape awareness, foster trust, and drive more meaningful engagement across the healthcare ecosystem. Focus on embedding authenticity into engagement strategies to better reflect and support rare disease communities.

• Understand the impact of authentic vs. generic representation on patient perception, stigma, and disease awareness
• Explore how initiatives like It's Rare for Me and True Faces of Rare can be operationalized to align communications with real patient experiences
• Identify actionable strategies to incorporate authentic patient voices and visuals across advocacy, education, and engagement efforts

Powerful case studies can demonstrate how to redefine partnerships and put patients at the center of everything—from strategy to storytelling. Drawing on film, podcast, and experiential campaigns, this session will demonstrate how authentic patient voices can shape culture, guide decision-making, and drive measurable impact across advocacy, education, and access. How can lived experience evolve from inspiration to infrastructure, turning patient stories into meaningful community impact and enduring organizational transformation?

• Explore a collaborative approach to embedding patient voices in strategy, storytelling, and culture.
• Understand how narrative-driven engagement builds empathy, alignment, and measurable impact.
• Gain practical insights for sustaining patient partnership and purpose across your organization.

Biopharma organizations are investing more than ever in patient advocacy, but the traditional methods to measure impact through reach, volume, and engagement counts are insufficient indicators of success. Leading companies are shifting toward outcomes-oriented approaches that demonstrate how patient engagement drives real positive impact across clinical, access, and commercial workstreams. Envision Pharma Group has developed a lifecycle-based patient advocacy and engagement measurement framework that evolves with product maturity, market dynamics, and PAG relationships. Real-world case studies provide a roadmap to move beyond static KPIs to adaptive approaches that link advocacy efforts to outcomes like recruitment, access, retention, and long-term trust.

• Shift from activity tracking to impact-driven measures
• Adapt impact measurements with product lifecycle priorities
• Leverage flexible, scalable frameworks to ensure cross-functional alignment

Embedding patient voice early in R&D often feels resource-intensive and difficult to scale. This session shares a matrix-based operating model and Patient Impact Roadmap that enables upstream integration of patient insights without relying on a large, dedicated patient engagement function.

• Discover how to embed patient voice early, from molecule selection through regulatory strategy
• Look at the design of a matrix model that aligns leadership oversight, functional expertise, and asset-level execution
• Go over practical ways to build organizational buy-in and break down cross-functional barriers
• Explore how integrated patient intelligence can strengthen target product profiles and development plans
• Lessons learned for scaling patient engagement in real-world organizational constraints

The regulatory landscape is evolving rapidly and staying ahead of legal and policy changes is critical for organizations in life sciences. This panel brings together FDA experts to discuss the most recent updates, share practical guidance, and provide clarity on how these changes may impact your programs and patient engagement strategies.

Patient Engagement is entering its next chapter. As the patient ecosystem becomes increasingly complex, organizations need new ways to consistently turn patient perspectives into better decisions at scale. The next chapter isn't about greater recognition. It's about building the capabilities that enable better patient-informed decisions. Patient Engagement is now approaching the same strategic inflection point that transformed Medical Affairs - what are the key principles of a new operating model? Organizations need to move from fragmented information and disconnected engagement activities to a structured approach that helps identify the right patient communities, coordinate engagement, preserve institutional knowledge, and enable better patient-informed decisions at scale.

The role of patient advocacy has evolved significantly in recent years, expanding the ways advocates influence research, access, and engagement. Gaining perspectives from several Chief patient officers, your team will learn how the role continues to evolve, how to address barriers to patient access, how to leverage technology to enhance patient engagement, and much more!

• Highlight the importance of incorporating patient perspectives throughout the trial process
• Discuss current challenges and trends that are happening today
• Gain insights into how different organizations address advocacy challenges and implement innovative solutions

Empowering patient advocacy leaders and their communities to co-create solutions and influence decision-making is key to building a robust advocacy platform. Overcoming internal barriers allows patients to participate strategically, ensuring their voices shape meaningful outcomes. How is your company empowering patient advocacy leaders and their communities to directly co-create solutions, influence decision-making, and even participate in governance structures at a truly strategic level within your organization?

• Identify the biggest internal barriers to deep patient co-creation
• Explore strategies to overcome these barriers and enable meaningful partnerships
• Examine methods to integrate patient advocacy leaders into governance and decision-making processes

Patient centricity has become a strategic imperative for high-performing clinical study operations and subsequent product success - but are we truly hitting the mark? Enterprise-wide expectations bring growing pressure to understand and align with patient and community needs, and to demonstrate a measurable return on engagement. This session brings into focus where patient and public preferences and actual research experiences converge, and where they do not, to help leaders in this space evolve their strategies with evidence and accountability.

• Explore CISCRP's latest global patient and public survey data on research perceptions, preferences and experiences, including AI, DCT, and key factors influencing participation decision-making (12,000+ respondents; 4,000+ clinical study participants)
• Discover key impact metrics from CISCRP's community engagement and outreach programs on effectively improving awareness, engagement, recruitment, and representation
• Juxtapose these insights with current regulator and organizational expectations to highlight the growing challenge of meeting patient and public preferences

The EMA has released a reflection paper on the use of patient experience data (PED) in drug development, outlining principles for integrating PED throughout the product lifecycle. With public comments now open, this guidance aims to support earlier diagnosis and improve patient care. Understanding these provisions provides insight into how patient experience data may influence practices globally, including in the U.S.

• Review the key principles outlined in the EMA reflection paper on patient experience data
• Discuss how these EU provisions may influence U.S. patient engagement and drug development practices
• Explore opportunities to integrate PED for earlier diagnosis and improved patient care